{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:50:37Z","timestamp":1791251437982,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07538-0","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:54:41Z","timestamp":1791248081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world durability of faricimab in treatment-na\u00efve nAMD patients: outcomes of an observe-and-plan regimen"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3524-9507","authenticated-orcid":false,"given":"Lennart Erik","family":"Scholand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-0199","authenticated-orcid":false,"given":"Torben Lykke","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"7538_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","volume":"104","author":"JQ Li","year":"2020","unstructured":"Li JQ, Welchowski T, Schmid M et al (2020) Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol 104:1077\u20131084. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314422","journal-title":"Br J Ophthalmol"},{"key":"7538_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"7538_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders. N Engl J Med 331:1480\u20131487. https:\/\/doi.org\/10.1056\/NEJM199412013312203","journal-title":"N Engl J Med"},{"key":"7538_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676. https:\/\/doi.org\/10.1038\/nm0603-669","journal-title":"Nat Med"},{"key":"7538_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"J Boyle","year":"2018","unstructured":"Boyle J, Vukicevic M, Koklanis K et al (2018) Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med 23:127\u2013140. https:\/\/doi.org\/10.1080\/13548506.2016.1274040","journal-title":"Psychol Health Med"},{"key":"7538_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF (2020) Visual Acuity Outcomes and Anti\u2013Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients. Ophthalmol Retina 4:19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.05.017","journal-title":"Ophthalmol Retina"},{"key":"7538_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","volume":"263","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ et al (2025) Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol 263:1239\u20131247. https:\/\/doi.org\/10.1007\/s00417-024-06695-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7538_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A et al (2024) TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology 131:914\u2013926. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"7538_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/eye.2014.258","volume":"29","author":"C Gianniou","year":"2015","unstructured":"Gianniou C, Dirani A, Ferrini W et al (2015) Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye 29:342\u2013349. https:\/\/doi.org\/10.1038\/eye.2014.258","journal-title":"Eye"},{"key":"7538_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","volume":"67","author":"R Mori","year":"2023","unstructured":"Mori R, Honda S, Gomi F et al (2023) Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol 67:301\u2013310. https:\/\/doi.org\/10.1007\/s10384-023-00985-w","journal-title":"Jpn J Ophthalmol"},{"key":"7538_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-024-00566-0","volume":"10","author":"N Nasimi","year":"2024","unstructured":"Nasimi N, Nasimi S, Grauslund J et al (2024) Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review. Int J Retina Vitr 10:48. https:\/\/doi.org\/10.1186\/s40942-024-00566-0","journal-title":"Int J Retina Vitr"},{"key":"7538_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1159\/000540194","volume":"67","author":"L Toto","year":"2024","unstructured":"Toto L, Formenti F, Ruggeri ML et al (2024) Efficacy and Durability of Faricimab in Na\u00efve Eyes with Neovascular Age-Related Macular Degeneration. Ophthalmic Res 67:528\u2013536. https:\/\/doi.org\/10.1159\/000540194","journal-title":"Ophthalmic Res"},{"key":"7538_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3928\/23258160-20250304-02","volume":"56","author":"FS Ali","year":"2025","unstructured":"Ali FS, Tabano DC, Borkar DS et al (2025) Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina 56:468\u2013477. https:\/\/doi.org\/10.3928\/23258160-20250304-02","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"7538_CR14","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H et al (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results. Eye 37:3574\u20133581. https:\/\/doi.org\/10.1038\/s41433-023-02553-5","journal-title":"Eye"},{"key":"7538_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40942-024-00586-w","volume":"10","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Paris A et al (2024) Intravitreal faricimab for treatment na\u00efve patients with neovascular age-related macular degeneration: a real-world prospective study. Int J Retina Vitr 10:70. https:\/\/doi.org\/10.1186\/s40942-024-00586-w","journal-title":"Int J Retina Vitr"},{"key":"7538_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R et al (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8:1265\u20131288. https:\/\/doi.org\/10.15252\/emmm.201505889","journal-title":"EMBO Mol Med"},{"key":"7538_CR17","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD et al (2020) Faricimab: expanding horizon beyond VEGF. Eye 34:802\u2013804. https:\/\/doi.org\/10.1038\/s41433-019-0670-1","journal-title":"Eye"},{"key":"7538_CR18","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cells9081869","volume":"9","author":"M Khan","year":"2020","unstructured":"Khan M, Aziz AA, Shafi NA et al (2020) Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells 9:1869. https:\/\/doi.org\/10.3390\/cells9081869","journal-title":"Cells"},{"key":"7538_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-020-00250-z","volume":"6","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Heier JS, Do DV et al (2020) The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retina Vitr 6:48. https:\/\/doi.org\/10.1186\/s40942-020-00250-z","journal-title":"Int J Retina Vitr"},{"key":"7538_CR20","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1186\/s12967-024-05441-y","volume":"22","author":"L Sha","year":"2024","unstructured":"Sha L, Zhao Y, Li S et al (2024) Insights to Ang\/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. J Transl Med 22:898. https:\/\/doi.org\/10.1186\/s12967-024-05441-y","journal-title":"J Transl Med"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07538-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07538-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07538-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:54:42Z","timestamp":1791248082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07538-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":20,"alternative-id":["7538"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07538-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was waived by both the local hospital management and the head of the ophthalmology department of Zealand University Hospital in Roskilde, in view of the retrospective nature of the study, and all the procedures being performed were part of the routine care.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}